
David A Shaywitz MD PhD
Diabetes, Lipid Metabolism, Obesity, Clinical Informatics
Founder, Astounding HealthTech Advisory Services. Rangy executive applying AI and digital technologies to biopharma and functional longevity. Player-coach.
Join to view full profile
0 Emerson PlSte 112Boston, MA 02114
Phone+1 617-726-7948
Fax+1 617-726-1241
Dr. Shaywitz is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Shaywitz is a physician-executive focused on the application of emerging technologies to biopharma and functional longevity. He pursued his MD/PhD at Harvard Medical School/MIT, continued his training in internal medicine and endocrinology at the Massachusetts General Hospital, and completed his post-doctoral fellowship in the Melton Lab at the Harvard Stem Cell Institute.
He works at the intersection of biopharma, AI, and digital health, helping organizations navigate the rapid evolution of emerging technologies and translate breakthroughs into real-world impact. His career has been built on identifying high-value innovations, connecting biopharma and tech, and guiding scientific and technological advances toward practical application in drug development, healthcare, and human performance.
As a physician-scientist and biopharma executive, he has worked across strategy, external innovation, investment, and digital transformation -- with a pragmatic focus on adoption and tangible patient benefit. He has partnered with startups, pharma leaders, and investors to help them integrate AI, wearables, and data-driven technologies into implementable solutions that advance R&D, enhance patient care, and promote functional longevity.
Education & Training
Harvard Stem Cell InstitutePost-Doctoral Fellowship, 2003 - 2006
Mass General Brigham/Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2002 - 2005
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999
Certifications & Licensure
MA State Medical License 2002 - 2028
Publications & Presentations
PubMed
- Context-aware monitoring: rethinking comprehensive screening in the era of AI.David A Shaywitz, Nathan D Price, Daniel K Sodickson
NPJ Digital Medicine. 2026-08-13 - Artificial intelligence in drug discovery - what it is, where we stand and the path forward.Andreas Bender, Morgan C Thomas, Jack W Scannell, David A Shaywitz, Gian Marco Ghiandoni
Nature Reviews. Drug Discovery. 2026-08-07 - AI: An essential tool for managing the burgeoning complexity of clinical development in pharmaceutical R&D.Subha Madhavan, David A Shaywitz
Drug Discovery Today. 2025-03-01
Authored Content
- AI Doesn't Ask Why -- but Physicians and Drug Developers Want to KnowNovember 2018
- The Future of Clinical Research Looks A Lot like Implementation ScienceAugust 2018
Press Mentions
- One of the Masterminds Behind Remdesivir, Gilead's Diana Brainard Jumps Ship to Antiviral T Cell Player AlloVirMarch 23rd, 2021
Why Trump’s Desperate Bid for A Win on COVID-19 Puts Lives at RiskAugust 25th, 2020
How Coronavirus Will Change Healthcare ForeverMay 18th, 2020
External Links
- Profilehttp://davidshaywitz.wordpress.com/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









